Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab or ...

ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Prostate-specific membrane antigen (PSMA) expression in renal cell carcinoma (RCC) was an incidental finding but shows potential. Uncertainty regarding frequency of PSMA expression across RCC subtypes ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

Dr Murray on pembrolizumab counseling: “I split treatments into those we continue to put inside your bladder that patients are familiar with, and then pembrolizumab, which is FDA approved but ...

The ARANOTE study had sufficient Black male representation for meaningful comparative analysis. Safety data from other clinical trials show similar patterns. Real-world evidence corroborates safety in ...

Future Directions for Imaging in Kidney Cancer Main Discussion Topics: Potential for deep learning and artificial intelligence (AI) to extract additional information from imaging data sets Recognition ...

ARANOTE’s overall survival data are still maturing. ARASENS data show a promising trend for survival benefit. Competing risks and care access issues complicate survival analysis. Treatment completion ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.

EV+P showed a higher complete response rate and longer duration of response than chemotherapy in urothelial carcinoma patients. The median overall survival and progression-free survival were ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...